William G. Tsiaras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
William G. Tsiaras has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Arash Mostaghimi
Department of Dermatology, Brigham and Women’s Hospital, Boston, USA
3 shared publications - Barbara Giovannone
Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
2 shared publications - Cara Joyce
Department of Medicine, Stritch School of Medicine, Loyola University Chicago, 2160 S 1st Ave, Maywood, IL 60153, USA
2 shared publications Corinne Lautier
Division of Endocrinology and
2 shared publications- Robert J. Smith
Division of Endocrinology, Department of Medicine, Alpert Medical School of Brown University, Providence, RI; Hallett Center for Diabetes and Endocrinology, Rhode Island Hospital, Providence, RI
2 shared publications - Stefano Goldwurm
Parkinson Institute, ASST "Gaetano Pini-CTO", Milan, Italy
2 shared publications
Latest Publications
- 1 August 2021
- Published by Elsevier in Journal of Tissue Viability
- Vol. 30 (3) , 462-464
Hydroxyurea-induced genital ulcers and erosions: Two case reports
- 1 August 2021
- Published by Elsevier in Journal of Tissue Viability
- Vol. 30 (3) , 462-464
Hydroxyurea-induced genital ulcers and erosions: Two case reports
- 15 October 2018
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 22 (6) , 650-651
Evaluating the Efficacy of Topical Dapsone Treatment for Pyoderma Gangrenosum: A Retrospective Case Series
- 15 October 2018
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 22 (6) , 650-651
Evaluating the Efficacy of Topical Dapsone Treatment for Pyoderma Gangrenosum: A Retrospective Case Series
- 1 April 2018
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 154 (4) , 409-+
The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum
Pyoderma gangrenosum is an inflammatory neutrophilic dermatosis. Current knowledge of this rare disease is limited owing to a lack of validated diagnostic criteria and large population studies. To evaluate the association of age with the clinical presentation and comorbidities of pyoderma gangrenosum. This was a multicenter retrospective cohort study performed at tertiary academic referral centers in urban settings. Adults (≥18 years) who were evaluated and diagnosed as having pyoderma gangrenosum at the Brigham and Women's and Massachusetts General Hospitals from 2000 to 2015 and the University of Pennsylvania Health System from 2006 to 2016 were included. Patient demographics, clinical features, medical comorbidities, and treatment. Of the 356 validated cases of pyoderma gangrenosum included in the study, 267 (75%) were women and 284 (84.8%) were white. The mean (SD) age at presentation was 51.6 (17.7) years. Pathergy was recorded in 100 patients (28.1%). A total of 238 patients (66.9%) had associated medical comorbidities: inflammatory bowel disease in 146 patients (41.0%); inflammatory arthritis in 73 patients (20.5%); solid organ malignant neoplasms in 23 patients (6.5%); hematologic malignant neoplasms in 21 patients (5.9%); and hematologic disorders, specifically monoclonal gammopathy of undetermined significance, myelodysplastic syndrome, and polycythemia vera in 17 patients (4.8%). When stratified by age, pathergy was more common in patients 65 years or older (36.3% vs 24.3%; P = .02). Inflammatory bowel disease was the only medical comorbidity that was more common in patients younger than 65 years (47.7% vs 26.6%; P < .001), while a number of medical comorbidities were more common in those 65 years or older, including rheumatoid arthritis (13.3% vs 6.2%; P = .03), ankylosing spondylitis (1.8% vs 0%; P = .04), solid organ malignant neoplasms (13.3% vs 3.3%; P < .001), hematologic malignant neoplasms (9.7% vs 4.1%; P = .04), and the aforementioned hematologic disorders (10.6% vs 2.1%; P < .001). Although clinical presentation in this large cohort was similar between different age groups, disease associations varied by age. The findings of this study may allow for a more focused, age-specific evaluation of patients with pyoderma gangrenosum.
- 1 April 2018
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 154 (4) , 409-+
The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum
Pyoderma gangrenosum is an inflammatory neutrophilic dermatosis. Current knowledge of this rare disease is limited owing to a lack of validated diagnostic criteria and large population studies. To evaluate the association of age with the clinical presentation and comorbidities of pyoderma gangrenosum. This was a multicenter retrospective cohort study performed at tertiary academic referral centers in urban settings. Adults (≥18 years) who were evaluated and diagnosed as having pyoderma gangrenosum at the Brigham and Women's and Massachusetts General Hospitals from 2000 to 2015 and the University of Pennsylvania Health System from 2006 to 2016 were included. Patient demographics, clinical features, medical comorbidities, and treatment. Of the 356 validated cases of pyoderma gangrenosum included in the study, 267 (75%) were women and 284 (84.8%) were white. The mean (SD) age at presentation was 51.6 (17.7) years. Pathergy was recorded in 100 patients (28.1%). A total of 238 patients (66.9%) had associated medical comorbidities: inflammatory bowel disease in 146 patients (41.0%); inflammatory arthritis in 73 patients (20.5%); solid organ malignant neoplasms in 23 patients (6.5%); hematologic malignant neoplasms in 21 patients (5.9%); and hematologic disorders, specifically monoclonal gammopathy of undetermined significance, myelodysplastic syndrome, and polycythemia vera in 17 patients (4.8%). When stratified by age, pathergy was more common in patients 65 years or older (36.3% vs 24.3%; P = .02). Inflammatory bowel disease was the only medical comorbidity that was more common in patients younger than 65 years (47.7% vs 26.6%; P < .001), while a number of medical comorbidities were more common in those 65 years or older, including rheumatoid arthritis (13.3% vs 6.2%; P = .03), ankylosing spondylitis (1.8% vs 0%; P = .04), solid organ malignant neoplasms (13.3% vs 3.3%; P < .001), hematologic malignant neoplasms (9.7% vs 4.1%; P = .04), and the aforementioned hematologic disorders (10.6% vs 2.1%; P < .001). Although clinical presentation in this large cohort was similar between different age groups, disease associations varied by age. The findings of this study may allow for a more focused, age-specific evaluation of patients with pyoderma gangrenosum.
- 16 February 2018
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 179 (1) , 216-217
The validity of the diagnostic code for pyoderma gangrenosum in an electronic database
- 16 February 2018
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 179 (1) , 216-217
The validity of the diagnostic code for pyoderma gangrenosum in an electronic database
- 1 February 2018
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 78 (2) , 310-314.e1
Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum—A retrospective analysis
- 1 February 2018
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 78 (2) , 310-314.e1
Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum—A retrospective analysis
- Open Access
- 1 March 2017
- Published by Elsevier in JAAD Case Reports
- Vol. 3 (2) , 110-112
Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab
- 1 March 2017
- Published by Elsevier in JAAD Case Reports
- Vol. 3 (2) , 110-112
Open AccessIntractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab
- 1 November 2015
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 151 (11) , 1199
Skin Autotomization and Regeneration—The African Spiny Mouse
Humanities from JAMA Dermatology — Skin Autotomization and Regeneration—The African Spiny Mouse
- 1 November 2015
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 151 (11) , 1199
Skin Autotomization and Regeneration—The African Spiny Mouse
Humanities from JAMA Dermatology — Skin Autotomization and Regeneration—The African Spiny Mouse
- 16 December 2013
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 49 (3) , 460-462
Total leukoderma and leukotrichia in a child after hematopoietic SCT: report of a case and review of the literature
- 16 December 2013
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 49 (3) , 460-462
Total leukoderma and leukotrichia in a child after hematopoietic SCT: report of a case and review of the literature
- 1 December 2013
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 149 (12) , 1427
Multiple Tense Bullae Localized to the Right Breast in a Woman in Her Seventies
- 1 December 2013
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 149 (12) , 1427
Multiple Tense Bullae Localized to the Right Breast in a Woman in Her Seventies
- 1 August 2013
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 149 (8) , 946-949
Intralesional Sodium Thiosulfate for the Treatment of Calciphylaxis
Case report from JAMA Dermatology — Intralesional Sodium Thiosulfate for the Treatment of Calciphylaxis
- 1 August 2013
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 149 (8) , 946-949
Intralesional Sodium Thiosulfate for the Treatment of Calciphylaxis
Case report from JAMA Dermatology — Intralesional Sodium Thiosulfate for the Treatment of Calciphylaxis